It is fantastic to see Gendius come through our programme and grow from the initial concept through to funding all under one roof.
BioHub success, Gendius set up virtual tenancy at the BioHub about 2 years ago and then went through the various ‘Bootcamp’ training days and mentoring programmes provided at the hub. Since being in residence Gendius has had successful grant application with Innovate UK and SBRI and this Venture Capital success comes on the back of pitching at one of the BioHub events.
Ned Wakeman – Director at BioHub said
“It is fantastic to see Gendius come through our programme and grow from the initial concept through to funding all under one roof. This is a great success story for the BioHub and will result in extra jobs based at the Park”.
Diabetes is a global epidemic. The economic cost of treating diabetes in 2014 is estimated at over $600bn and the latest WHO report predicts there will be 592m sufferers around the world by 2035. Healthcare systems are desperate for novel solutions to engage and empower people to manage their diabetes more effectively and mobile technologies are spearheading many of these initiatives, and are predicted to be worth US$102.43bn by 2022, largely driven by Applications.
Gendius was founded by Chris Genders and Rory Cameron with a view to making living with diabetes easier. The company has developed Intellin® – an App platform that uses an individual’s clinical history to predict those areas most likely of developing complications from their diabetes i.e. their individual high-risk areas. The platform then focuses the individual on clinically validated tasks and measures to slow their progression in these areas. The Intellin® platform is currently undergoing clinical trials and has won significant grant funding from both Innovate UK and the SBRI.
In addition to the investment, Chris Spencer, a Digital Health Advisor with Catapult Ventures, will join the board of Gendius as non-executive Chairman in early 2018. Until April 2017 Chris was CEO of EMIS Group Plc where he had held senior roles since 1999.
Chris Genders, CEO Gendius, said
“I’m extremely pleased to welcome the GM&C Life Sciences Fund as an investor in Gendius and welcome Chris as Chair elect. Chris’s wide-ranging experience in the leadership and management of healthcare technology businesses will be extremely valuable to Gendius as we seek to further enhance and commercialize our digital applications for diabetes and grow Gendius as a leader in this area.”
Dr Vijay Barathan, Life Science Partner with Catapult Ventures said
“We are excited by this opportunity and fully support the approach Gendius is taking to develop a scalable and sustainable digital health business.”
Chris Spencer, Digital Health Advisor with Catapult Ventures, said
“I am looking forward to working with Chris, Rory, and the team to fulfil the potential of their application to improve clinical outcomes in this area of high patient need and payer/provider cost.”